Haruyasu Murakami

9.2k total citations · 1 hit paper
306 papers, 6.1k citations indexed

About

Haruyasu Murakami is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Haruyasu Murakami has authored 306 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 223 papers in Pulmonary and Respiratory Medicine, 216 papers in Oncology and 54 papers in Molecular Biology. Recurrent topics in Haruyasu Murakami's work include Lung Cancer Treatments and Mutations (197 papers), Lung Cancer Research Studies (106 papers) and Lung Cancer Diagnosis and Treatment (64 papers). Haruyasu Murakami is often cited by papers focused on Lung Cancer Treatments and Mutations (197 papers), Lung Cancer Research Studies (106 papers) and Lung Cancer Diagnosis and Treatment (64 papers). Haruyasu Murakami collaborates with scholars based in Japan, United States and Taiwan. Haruyasu Murakami's co-authors include Toshiaki Takahashi, Masahiro Endo, Nobuyuki Yamamoto, Tateaki Naito, Akira Ono, Hirotsugu Kenmotsu, Yukiko Nakamura, Kyoichi Kaira, Asuka Tsuya and Takehito Shukuya and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Haruyasu Murakami

288 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Kazuhiko Nakagawa, Haruyasu Murakami et al. profile →

Peers

Haruyasu Murakami

ONCOL

PRM

EPIDE

Giuseppe Procopio Italy

Hiroshi Nokihara Japan

Takashi Seto Japan

Miyako Satouchi Japan

Hagen F. Kennecke Canada

Koji Tsuta Japan

Yukitoshi Satoh Japan

Tae‐You Kim South Korea

Otilia Dalesio Netherlands

Maria Di Bartolomeo Italy

Giuseppe Procopio Italy

Haruyasu Murakami

2.7k ×0.7

ONCOL

3.1k ×0.8

PRM

1.5k ×1.1

1.2k ×1.4

986 ×1.4

EPIDE

Citations per year, relative to Haruyasu Murakami Haruyasu Murakami (= 1×) peers Giuseppe Procopio

Countries citing papers authored by Haruyasu Murakami

Since Specialization

Citations

This map shows the geographic impact of Haruyasu Murakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haruyasu Murakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haruyasu Murakami more than expected).

Fields of papers citing papers by Haruyasu Murakami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haruyasu Murakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haruyasu Murakami. The network helps show where Haruyasu Murakami may publish in the future.

Co-authorship network of co-authors of Haruyasu Murakami

This figure shows the co-authorship network connecting the top 25 collaborators of Haruyasu Murakami. A scholar is included among the top collaborators of Haruyasu Murakami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haruyasu Murakami. Haruyasu Murakami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations

Nakashima, Kazuhisa, Haruyasu Murakami, Toshiaki Takahashi, et al.. (2024). Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status. Respiratory Investigation. 62(6). 1137–1141.

Naito, Tateaki, Keita Miura, Yuko Iida, et al.. (2024). Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study. Thoracic Cancer. 15(25). 1831–1841. 2 indexed citations

Murakami, Haruyasu, Nobuaki Mamesaya, Shota Omori, et al.. (2024). Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer. Thoracic Cancer. 15(21). 1665–1672. 1 indexed citations

Niho, Seiji, Jun Sato, Miyako Satouchi, et al.. (2024). Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 191. 107557–107557. 6 indexed citations

Tsuboi, Masahiro, Haruyasu Murakami, Hideyuki Harada, et al.. (2024). Treatment patterns and clinical outcomes of resectable clinical stage III non‐small cell lung cancer in a Japanese real‐world setting: Surgery cohort analysis of the SOLUTION study. Thoracic Cancer. 15(20). 1541–1552. 1 indexed citations

Murakami, Haruyasu, Keita Miura, Yuko Iida, et al.. (2023). Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer. Thoracic Cancer. 14(35). 3475–3482. 1 indexed citations

Ohe, Yuichiro, Naoya Yamazaki, Nobuyuki Yamamoto, et al.. (2022). The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Japanese Journal of Clinical Oncology. 52(6). 623–632. 7 indexed citations

Kenmotsu, Hirotsugu, Chiyo K. Imamura, Takahisa Kawamura, et al.. (2022). Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients. Cancer Chemotherapy and Pharmacology. 90(2). 115–123. 3 indexed citations

10.

Nishioka, Naoya, Tateaki Naito, Taichi Miyawaki, et al.. (2022). Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer. Thoracic Cancer. 13(10). 1496–1504. 12 indexed citations

11.

Omori, Shota, Takanori Kawabata, Naoya Nishioka, et al.. (2022). Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy. Advances in Radiation Oncology. 8(2). 101129–101129. 4 indexed citations

12.

Miyawaki, Taichi, Hirotsugu Kenmotsu, Naoya Nishioka, et al.. (2022). Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer. Cancer Medicine. 12(2). 1451–1460. 4 indexed citations

13.

Kenmotsu, Hirotsugu, Takanori Kawabata, Akifumi Notsu, et al.. (2021). Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation. Cancer Medicine. 10(21). 7503–7513. 4 indexed citations

14.

Fujiwara, Yutaka, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.. (2021). Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Medicine. 10(7). 2350–2358. 10 indexed citations

15.

Miyawaki, Taichi, Kazushige Wakuda, Hirotsugu Kenmotsu, et al.. (2020). Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy. Cancer Science. 112(1). 359–368. 8 indexed citations

16.

Ono, Akira, Haruyasu Murakami, Takashi Seto, et al.. (2020). Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. Drugs in R&D. 21(1). 65–78. 4 indexed citations

17.

Nishioka, Naoya, Tateaki Naito, Akifumi Notsu, et al.. (2020). Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer. Cancer Medicine. 10(1). 247–256. 30 indexed citations

18.

Ito, Kimihiro, Makoto Nishio, Masanori Kato, et al.. (2019). TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X. Molecular Cancer Therapeutics. 18(5). 920–928. 10 indexed citations

19.

Nakashima, Kazuhisa, Tateaki Naito, Haruki Kobayashi, et al.. (2019). Platinum Combination Chemotherapy Is Poorly Tolerated in Malnourished Advanced Lung Cancer Patients with Poor Performance Status. Nutrition and Cancer. 71(5). 767–771. 7 indexed citations

20.

Murakami, Haruyasu, Nobuyuki Yamamoto, Taro Shibata, et al.. (2014). A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84(1). 67–72. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact